135 related articles for article (PubMed ID: 37232564)
21. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.
Kadoyama K; Kuwahara A; Yamamori M; Brown JB; Sakaeda T; Okuno Y
J Exp Clin Cancer Res; 2011 Oct; 30(1):93. PubMed ID: 21970649
[TBL] [Abstract][Full Text] [Related]
22. Botulinum toxin for palliative treatment of epiphora in a patient with canalicular obstruction.
Tu AH; Chang EL
Ophthalmology; 2005 Aug; 112(8):1469-71. PubMed ID: 15953639
[TBL] [Abstract][Full Text] [Related]
23. A cross-sectional optical coherence tomography study in patients on taxane-based therapy and a case report with the literature review.
Kaya M; Atas F; Gulsum Guc Z; Oztop I; Durak I; Saatci AO
Cutan Ocul Toxicol; 2020 Sep; 39(3):287-293. PubMed ID: 32619362
[TBL] [Abstract][Full Text] [Related]
24. Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: underestimated dose-limiting toxicity.
Tsalic M; Gilboa M; Visel B; Miller B; Haim N
Med Oncol; 2006; 23(1):57-61. PubMed ID: 16645230
[TBL] [Abstract][Full Text] [Related]
25. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
Nomura H; Aoki D; Michimae H; Mizuno M; Nakai H; Arai M; Sasagawa M; Ushijima K; Sugiyama T; Saito M; Tokunaga H; Matoda M; Nakanishi T; Watanabe Y; Takahashi F; Saito T; Yaegashi N;
JAMA Oncol; 2019 Jun; 5(6):833-840. PubMed ID: 30896757
[TBL] [Abstract][Full Text] [Related]
26. Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary UK cancer centres.
Chan J; Adderley H; Alameddine M; Armstrong A; Arundell D; Fox R; Harries M; Lim J; Salih Z; Tetlow C; Wong H; Thorp N
Eur J Cancer Care (Engl); 2021 May; 30(3):e13395. PubMed ID: 33350015
[TBL] [Abstract][Full Text] [Related]
27. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
[TBL] [Abstract][Full Text] [Related]
28. Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
Curr Med Res Opin; 2013 Feb; 29(2):117-25. PubMed ID: 23216340
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel secretion in tears: association with lacrimal drainage obstruction.
Esmaeli B; Ahmadi MA; Rivera E; Valero V; Hutto T; Jackson DM; Newman RA
Arch Ophthalmol; 2002 Sep; 120(9):1180-2. PubMed ID: 12215091
[TBL] [Abstract][Full Text] [Related]
30. Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.
Nyrop KA; Deal AM; Reeder-Hayes KE; Shachar SS; Reeve BB; Basch E; Choi SK; Lee JT; Wood WA; Anders CK; Carey LA; Dees EC; Jolly TA; Kimmick GG; Karuturi MS; Reinbolt RE; Speca JC; Muss HB
Cancer; 2019 Sep; 125(17):2945-2954. PubMed ID: 31090930
[TBL] [Abstract][Full Text] [Related]
31. Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions.
Lansinger OM; Biedermann S; He Z; Colevas AD
J Clin Oncol; 2021 Nov; 39(32):3583-3590. PubMed ID: 34357780
[TBL] [Abstract][Full Text] [Related]
32. The postsaccal, idiopathic dacryostenosis--experimental and clinical aspects.
Steinkogler FJ
Doc Ophthalmol; 1986 Sep; 63(3):265-86. PubMed ID: 3780377
[TBL] [Abstract][Full Text] [Related]
33. Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system.
Wu Z; Zhou P; He N; Zhai S
Front Cardiovasc Med; 2022; 9():966331. PubMed ID: 36352852
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy.
Chan A; Su C; de Boer RH; Gajdatsy A
J Clin Oncol; 2013 Jun; 31(17):2123-7. PubMed ID: 23650421
[TBL] [Abstract][Full Text] [Related]
35. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel.
Esmaeli B; Amin S; Valero V; Adinin R; Arbuckle R; Banay R; Do KA; Rivera E
J Clin Oncol; 2006 Aug; 24(22):3619-22. PubMed ID: 16877729
[TBL] [Abstract][Full Text] [Related]
36. Erosive conjunctivitis and punctal stenosis secondary to docetaxel (taxotere).
Skolnick CA; Doughman DJ
Eye Contact Lens; 2003 Apr; 29(2):134-5. PubMed ID: 12695719
[TBL] [Abstract][Full Text] [Related]
37. Docetaxel-associated epiphora.
Kintzel PE; Michaud LB; Lange MK
Pharmacotherapy; 2006 Jun; 26(6):853-67. PubMed ID: 16716138
[TBL] [Abstract][Full Text] [Related]
38. Taxane-Induced Peripheral Neuropathy: Objective and Subjective Comparison Between Paclitaxel and Docetaxel in Patients With Breast Cancer.
Chan YN; Jheng YW; Wang PJ; Chen CY; Lin MW; Wang YJ
Clin J Oncol Nurs; 2019 Oct; 23(5):494-501. PubMed ID: 31538967
[TBL] [Abstract][Full Text] [Related]
39. Evaluation and Management of Chemotherapy-Induced Epiphora, Punctal and Canalicular Stenosis, and Nasolacrimal Duct Obstruction.
Mansur C; Pfeiffer ML; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2017; 33(1):9-12. PubMed ID: 27429222
[TBL] [Abstract][Full Text] [Related]
40. Association Between Pentosan Polysulfate Sodium and Retinal Disorders.
McGwin G; MacLennan P; Owsley C
JAMA Ophthalmol; 2022 Jan; 140(1):37-42. PubMed ID: 34792558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
